Troy Rafferty of Levin Papantonio Selected to Team of Attorneys to Lead Abilify Litigation | Levin Papantonio - Personal Injury Lawyers

Troy Rafferty of Levin Papantonio Selected to Team of Attorneys to Lead Abilify Litigation

Award winning personal injury attorney Troy Rafferty, a shareholder with the Levin Papantonio Law Firm, has been appointed to the leadership team handling cases related to the Abilify (Aripiprazole) Products Liability Litigation.

Federal judge Casey Rodgers with the U.S. District Court, Northern District of Florida, Pensacola Division announced the leadership appointments this week, for the Abilify MDL (2734). Rafferty is one of five members selected to be a part of the Plaintiffs’ Executive Committee. The decision was based on a comparison of the applicants’ relevant MDL experience and number of cases filed in this MDL.

Abilify is an antipsychotic medication that has been linked to complaints of compulsive behavior like gambling and hyper-sexuality. The U.S. Food and Drug Administration approved Abilify in November 2002, for the treatment of schizophrenia, bipolar disorder and other behavioral issues including depression and aggression.

Not long after Abilify was approved for use in the United States, some patients reported experiencing intense compulsive behavior, including gambling, sexual activity, shopping, and binge eating. Several medical studies have shown a link in some patients, between Abilify and compulsive, addictive behaviors.

In March 2016, the FDA issued a safety communication, warning doctors and patients that using Abilify could cause uncontrollable urges that can be dangerous if left untreated. Plaintiffs have now filed lawsuits against the manufacturers of Abilify, Bristol-Myers Squibb and Otsuka Pharmaceuicals, alleging the companies failed to warn them that compulsive behavior could be a side effect of the antipsychotic medication. Some are now seeking compensation for treatment of compulsive behavior, severe emotional injuries, and recovery of money to gambling.